Local Triamcinolone Injection in Active Thyroid Orbitopathy
NCT ID: NCT01280214
Last Updated: 2011-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2011-02-28
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function
NCT00561236
Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease
NCT04936854
Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections
NCT01599273
Topical Steroid Treatment For Dry Eye
NCT02218827
The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy
NCT01579539
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study the investigators want to compare the effectiveness of local Triamcinolone therapy for active thyroid orbitopathy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Triamcinolone
Triamcinolone
Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triamcinolone
Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Active thyroid orbitopathy according to clinical activity score\>=3.
Exclusion Criteria
* Tuberculosis.
* Other orbital disease.
* Pregnancy.
* Compressive optic neuropathy.
* Systemic steroid therapy within 6 months of study start.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Haemek Medical center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Briscoe, MD
Role: STUDY_CHAIR
haemek medical center
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMC119710ctil
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.